Applications of magnetic resonance spectroscopy in radiotherapy treatment planning

British Journal of Radiology

Volumn 79, Issue SPEC. ISS., 2006, Pages

  Payne, G S ^a   Leach, M O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CHOLINE; CITRIC ACID; CREATINE; INOSITOL; LACTIC ACID; LIPID; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ASTROCYTOMA; BIOCHEMISTRY; BRAIN CANCER; BRAIN METASTASIS; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL ACTIVITY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; HUMAN; IMAGE DISPLAY; IMAGE QUALITY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL SPECIALIST; MENINGIOMA; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; RADIATION NECROSIS; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR VOLUME;

BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PATIENT CARE PLANNING; PROSTATIC NEOPLASMS;

EID: 33750355465     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/84072695     Document Type: Article

References (65)

1. Gadian DG. Nuclear magnetic resonance and its applications to living systems. Oxford University Press, 1982.
2. de Graaf RA. In vivo NMR spectroscopy - principles and techniques. John Wiley & Sons Ltd, 1998.
3. Cornel EB, Smits GA, Oosterhof GO, Karthaus HF, Deburyne FM, Schalken JA, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 1993;150:2019-24.
4. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-5.
5. Khoo VS, Padhani AR, Tanner SF, Finnigan DJ, Leach MO, Dearnaley DP. Comparison of MM with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol 1999;72:590-7.
6. Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002;224:701-6.
7. Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999;43:57-66.
8. Roach M III, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-8.
9. Norris DG. High field human imaging. J Magn Reson Imaging 2003;18:519-29.
10. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-53.
11. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95:1624-33.
12. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-6.
13. Dewhirst MW, Poulson JM, Yu D, Sanders L, Lora-Michiels M, Vujaskovic Z, et al. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys 2005;61:480-91.
14. Findlay MP, Leach MO, Cunningham D, Collins DJ, Payne GS, Glaholm J, et al. The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann Oncol 1993;4:597-602.
15. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333-48.
16. Frahm J, Merboldt K, Hanicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987;72:502-8.
17. Ordidge RJ, Connelly A, Lohman AB. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 1986;66:283-94.
18. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA 1982;79:3523-6.
19. Chen Z, Ma CM, Paskalev K, Li J, Yang J, Richardson T, et al. Investigation of MR image distortion for radiotherapy treatment planning of prostate cancer. Phys Med Biol 2006;51:1393-403.
20. Reinsberg SA, Doran SJ, Charles-Edwards EM, Leach MO. A complete distortion correction for MR images: II. Rectification of static-field inhomogeneities by similarity-based profile mapping. Phys Med Biol 2005;50:2651-61.
21. Doran SJ, Charles-Edwards L, Reinsberg SA, Leach MO. A complete distortion correction for MR images: I. Gradient warp correction. Phys Med Biol 2005;50:1343-61.
22. Lee YK, Bollet M, Charles-Edwards G, Flower MA, Leach MO, McNair H, et al. Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging alone. Radiother Oncol 2003;66:203-16.
23. Veninga T, Huisman H, van der Maazen RW, Huizenga H. Clinical validation of the normalized mutual information method for registration of CT and MR images in radiotherapy of brain tumors. J Appl Clin Med Phys 2004;5:66-79.
24. Ehman RL, Felmlee JP. Adaptive technique for high-definition MR imaging of moving structures. Radiology 1989;173:255-63.
25. Cheng LL, Lean CL, Bogdanova A, Wright SC Jr, Ackerman JL, Brady TJ, et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med 1996;36:653-8.
26. Murphy PS, Dzik-Jurasz AS, Leach MO, Rowland IJ. The effect of Gd-DTPA on T(1)-weighted choline signal in human brain tumours. Magn Reson Imaging 2002;20:127-30.
27. Smith JK, Castillo M, Kwock L. MR spectroscopy of brain tumors. Magn Reson Imaging Clin N Am 2003;11:415-29, v-vi.
28. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-32.
29. Tate AR, Majos C, Moreno A, Howe FA, Griffiths JR, Arus C. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med 2003;49:29-36.
30. Majos C, Alonso J, Aguilera C, Serrallonga M, Perez-Martin J, Acebes JJ, et al. Proton magnetic resonance spectroscopy ((1)H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003;13:582-91.
31. Leclerc X, Huisman TA, Sorensen AG. The potential of proton magnetic resonance spectroscopy ((1)H-MRS) in the diagnosis and management of patients with brain tumors. Curr Opin Oncol 2002;14:292-8.
32. Maldjian JA, Patel RS. Cerebral neoplasms in adults. Semin Roentgenol 1999;34:102-22.
33. Lee PL, Gonzalez RG. Magnetic resonance spectroscopy of brain tumors. Curr Opin Oncol 2000;12:199-204.
34. Devos A, Lukas L, Suykens JA, Vanhamme L, Tate AR, Howe FA, et al. Classification of brain tumours using short echo time 1H MR spectra. J Magn Reson 2004;170:164-75.
35. Julia-Sape M, Acosta D, Mier M, Arus C, Watson D. A multi-centre, web-accessible and quality control-checked database of in vivo MR spectra of brain tumour patients. MAGMA 2006;19:22-33.
36. Jacobs AH, Kracht LW, Gossmann A, Ruger MA, Thomas AV, Thiel A, et al. Imaging in neurooncology. NeuroRx 2005;2:333-47.
37. Nelson SJ, Graves E, Pirzkall A, Li X, Chan AA, Vigneron DB, et al. In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J Magn Reson Imaging 2002;16:464-76.
38. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, et al. 3D MRSI for resected high-grade ghomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys; 2004;59:126-37.
39. Chan AA, Lau A, Pirzkall A, Chang SM, Verhey LJ, Larson D, et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J Neurosurg 2004;101:467-75.
40. Walecki J, Tarasow E, Kubas B, Czemicki Z, Lewko J, Podgorski J, et al. Hydrogen-1 MR spectroscopy of the peritumoral zone in patients with cerebral glioma: assessment of the value of the method. Acad Radiol 2003;10:145-53.
41. Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497-507.
42. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004;90:781-6.
43. Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, et al. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:20-31.
44. Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TICI single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. J Neurosurg 2004;100:835-41.
45. Chernov MF, Hayashi M, Izawa M, Abe K, Usukura M, Ono Y, et al. Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery: 1H-MRS study. Brain Tumor Pathol 2004;21:63-7.
46. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-63.
47. Cunningham CH, Vigneron DB, Marjanska M, Chen AP, Xu D, Hurd RE, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005;53:1033-9.
48. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991;18:25-46.
49. Kim Y, Noworolski S, Pouliot J, Hsu IC, Kurhanewicz J. Analysis of prostate deformation due to different MRI/MRS endorectal coils for image fusion and brachytherapy treatment planning. Med Phys 2004;31:1728.
50. Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y, et al. Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging 2002;16:697-706.
51. van Dorsten FA, van der GM, Engelbrecht MR, van Leenders GJ, Verhofstad A, Rijpkema M, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-87.
52. Shukla-Dave A, Hricak H, Pucar D, Kattan MW, Kuroiwa K, Chen H, et al. Indolent prostate cancer-prediction by magnetic resonance imaging and spectroscopy. Proceedings of the 13th Scientific Meeting of the International Society for Magnetic Resonance in Medicine. 2005;262:60.
53. Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004;183:1079-83.
54. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M III. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004;60:1047-55.
55. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LZ, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-80.
56. Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, Ito K, et al. The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003;23:4223-7.
57. Scheenen T, Weiland E, Futterer J, van Hecke P, Bachert P, Villeirs G, et al. Preliminary results of IMAPS: an international multi-centre assessment of prostate MR spectroscopy. Proceedings of the 13th Scientific Meeting of the International Society for Magnetic Resonance in Medicine. 2005;260:59.
58. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat 2004;3:591-8.
59. Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M III, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004;233:441-8.
60. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intraprostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999;44:921-9.
61. Pouliot J, Kim Y, Lessard E, Hsu IC, Vigneron DB, Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004;59:1196-207.
62. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M III. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001;51:244-54.
63. Murphy PS, Rowland IJ, Viviers L, Brada. M, Leach MO, Dzik-Jurasz AS. Could assessment of glioma methylene lipid resonance by in vivo (1)H-MRS be of clinical value? Br J Radiol 2003;76:459-63.
64. Chiang IC, Kuo YT, Lu CY, Yeung KW, Lin WC, Sheu FO, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004;46:619-27.
65. Yeung DK, Chan Y, Leung S, Poon PM, Pang C. Detection of an intense resonance at 2.4 ppm in 1H MR spectra of patients with severe late-delayed, radiation-induced brain injuries. Magn Reson Med 2001;45:994-1000.